Mark W. Lingen
Papers
2
Total Citations
57
H-Index
2
About
Mark W. Lingen is a leading pathologist and researcher whose work centers on the molecular pathogenesis of head and neck cancer, with a particular focus on human papillomavirus-positive oropharyngeal cancer (HPV+ OPC). His major contributions lie in pioneering neoadjuvant immunotherapy strategies to redefine curative treatment paradigms. Dr. Lingen has been instrumental in demonstrating that immune checkpoint inhibitors, such as nivolumab, combined with chemotherapy, can be effectively used prior to surgery, allowing for response-adaptive, de-intensified therapies that aim to reduce treatment toxicity without compromising survival. His landmark 2024 study on neoadjuvant nivolumab plus chemotherapy (45 citations) and the TARGET-HPV trial evaluating a novel HPV16-specific arenavirus-based immunotherapy (HB-200) are defining works in this space. These investigations are critical for moving beyond one-size-fits-all approaches toward precision, response-stratified care. With a career spanning decades, his work has profoundly shaped the understanding of oral cancer risk assessment and biomarker development. Dr. Lingen’s research continues to drive the shift toward less morbid, more effective treatments for patients with HPV-driven oropharyngeal cancers.
Research Focus
Key Achievements
Top Papers
- 1
- 2